The important discovery that programmed death ligand 1 (PD-L1) expression on tumor cells inhibits programmed cell death 1 (PD-1) on T cells to escape immune surveillance has opened an era of tumor immunotherapy1–4. This evidence concerns the gene PDCD1 and neoplasm.